The Genetics of Autoinflammatory Syndromes

Systemic autoinflammatory diseases result from pathogenic variants in genes governing innate and cell-intrinsic immune pathways, leading to dysregulated sterile or overexuberant inflammation. The field has expanded rapidly from a handful of hereditary fever syndromes to a diverse spectrum of conditions that are far more common than previously imagined. Key pathways found to be recurrently involved include the inflammasome, tumor necrosis factor (TNF)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and type I interferon signaling pathways. Mechanistic dissection of these disorders has driven the development of targeted therapies, including interleukin 1, TNF, and Janus kinase inhibitors. Such drugs have transformed patient outcomes for these genetic disorders and related common inflammatory conditions. This review examines the molecular pathophysiology, genetic paradigms, and emerging therapeutic strategies across the major categories of systemic autoinflammatory diseases.

Authors

Institutions

Publication Details

Journal
Annual Review of Medicine
Published
2026-11-17
DOI
https://doi.org/10.1146/annurev-med-042425-054729
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Genetics of Autoinflammatory Syndromes

Oskar Schnappauf, Xiao P. Peng, Ivona Aksentijevich
2 links
Annual Review of Medicine
Inflammasome and immune disorders
article

The Genetics of Autoinflammatory Syndromes

Oskar Schnappauf, Xiao P. Peng, Ivona Aksentijevich
article en

Abstract

Systemic autoinflammatory diseases result from pathogenic variants in genes governing innate and cell-intrinsic immune pathways, leading to dysregulated sterile or overexuberant inflammation. The field has expanded rapidly from a handful of hereditary fever syndromes to a diverse spectrum of conditions that are far more common than previously imagined. Key pathways found to be recurrently involved include the inflammasome, tumor necrosis factor (TNF)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and type I interferon signaling pathways. Mechanistic dissection of these disorders has driven the development of targeted therapies, including interleukin 1, TNF, and Janus kinase inhibitors. Such drugs have transformed patient outcomes for these genetic disorders and related common inflammatory conditions. This review examines the molecular pathophysiology, genetic paradigms, and emerging therapeutic strategies across the major categories of systemic autoinflammatory diseases.

Annual Review of Medicine
National Institutes of Health (US), Albert Einstein College of Medicine (US), Montefiore Medical Center (US), Hochschule Bonn-Rhein-Sieg (DE), National Human Genome Research Institute (US), Children's Hospital at Montefiore (US)
Good health and well-being
Inflammasome and immune disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon